PACIRA BIOSCIENCES, INC. Accrued Investment Income Receivable
PACIRA BIOSCIENCES, INC. (PCRX) had Accrued Investment Income Receivable of $500.00 thousand as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Balance Sheet › Assets
us-gaap:AccruedInvestmentIncomeReceivable · last filed 2025-02-27
- 2024-12-31: Accrued Investment Income Receivable $500.00K.
- 2023-12-31: Accrued Investment Income Receivable $400.00K.
- 2022-12-31: Accrued Investment Income Receivable $800.00K.
- 2021-12-31: Accrued Investment Income Receivable $100.00K.
| Period end | Accrued Investment Income Receivable |
|---|---|
| 2024-12-31 | $500.00K 10-K · filed 2025-02-27 |
| 2023-12-31 | $400.00K 10-K · filed 2025-02-27 |
| 2022-12-31 | $800.00K 10-K · filed 2024-02-29 |
| 2021-12-31 | $100.00K 10-K · filed 2023-02-28 |
| 2020-12-31 | $1.60M 10-K · filed 2022-02-28 |
| 2019-12-31 | $1.40M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |